Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Public ClinicalTrials.gov record NCT07287917. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Trial Investigating the Safety and Efficacy of Oral AMXT 1501 and Oral DFMO in Combination With Standard of Care in Patients With Advanced Solid Tumors Who Progressed After Prior Therapies
Study identification
- NCT ID
- NCT07287917
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Aminex Therapeutics, Inc.
- Industry
- Enrollment
- 92 participants
Conditions and interventions
Interventions
- AMXT 1501 Dicaprate Drug
- Capivasertib Drug
- DFMO Drug
- Fulvestrant Drug
- Pembrolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 25, 2026
- Primary completion
- Feb 27, 2028
- Completion
- Dec 28, 2028
- Last update posted
- May 4, 2026
2026 – 2028
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| START Los Angeles | Los Angeles | California | 90025 | Recruiting |
| Skin Cancer Institute | Englewood | Colorado | 80113 | Recruiting |
| Wayne State University - Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | Recruiting |
| START Cancer Research New York-Long Island | Lake Success | New York | 11042 | Recruiting |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45219 | Recruiting |
| Vanderbilt-Ingram Cancer Institute | Nashville | Tennessee | 37232 | Recruiting |
| University of Texas-MD Anderson | Houston | Texas | 77030 | Recruiting |
| Lumi Research | Houston | Texas | 77090 | Recruiting |
| Laguna Clinical Research Associates | Laredo | Texas | 78041 | Recruiting |
| START Mountain Region | West Valley City | Utah | 84119 | Recruiting |
| Virginia Cancer Specialists-Fairfax | Fairfax | Virginia | 22031 | Recruiting |
| University of Wisconsin-Madison Carbone Cancer Center | Madison | Wisconsin | 53706 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07287917, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 4, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07287917 live on ClinicalTrials.gov.